Mar 13, 2019 8:30 am EDT Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
Feb 25, 2019 8:30 am EST Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
Feb 13, 2019 8:30 am EST Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
Feb 6, 2019 8:30 am EST Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Jan 30, 2019 7:00 am EST Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
Dec 3, 2018 9:00 am EST Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
Nov 28, 2018 4:05 pm EST Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability